32 Biosciences vs Mabylon
32 Biosciences vs Mabylon, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: 32 Biosciences is on 42/100 and Mabylon on 35/100.
Where each one leads
32 Biosciences
- our overall score: 42/100 against 35/100
Mabylon
- agent readiness: 30/100 against 21/100
- domain rating: 32/100 against 13/100
- funding raised: $35.8M against $12.0M
At a glance
| Measure | 32 Biosciences | Mabylon |
|---|---|---|
| What it is | Develops novel therapeutic antibodies for oncology and autoimmune diseases. | Mabylon is a biotechnology company focused on developing innovative antibody-based therapies for infectious diseases and cancer. |
| Category | Biotech, Drug Discovery, Oncology, Autoimmune Diseases | Biotech, MedTech, Drug Discovery, Antibody Therapeutics |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Platform |
| Founded | 2017 | Not published |
| Headquarters | San Diego, United States | Geneva, Switzerland |
| Status | Active | Active |
Size, funding and growth
| Measure | 32 Biosciences | Mabylon |
|---|---|---|
| Employees | 9 | Not published |
| Total funding | $12.0M | $35.8M |
| Latest round | Not published | Series A |
| LinkedIn followers | 926 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | 32 Biosciences | Mabylon |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 42/100 | 35/100 |
| Traction | 45/100 | 38/100 |
| Team | 30/100 | Not published |
| Community | 3/100 | Not published |
| Search visibility | 24/100 | 2/100 |
| Quality | 48/100 | 45/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (30/100) |
| Domain ratingLink authority, 0-100 | 13/100 | 32/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | 32 Biosciences | Mabylon |
|---|---|---|
| Hosting | Self Managed | Self Managed |
| CMS | WordPress | Not detected |
| Frameworks | Jquery | Jquery, Bootstrap |
| Analytics | Google Analytics 4 | Google Analytics 4 |
What users say
| Measure | 32 Biosciences | Mabylon |
|---|---|---|
| Community ratingVisitor votes on StartupHub | 1.0/5 from 1 vote | Not published |
32 Biosciences vs Mabylon: common questions
Which is better, 32 Biosciences or Mabylon?
On our 0-100 score 32 Biosciences rates higher (42/100 against 35/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.
How do 32 Biosciences and Mabylon compare on the numbers?
32 Biosciences leads on our overall score (42/100 against 35/100). Mabylon leads on agent readiness (30/100 against 21/100), domain rating (32/100 against 13/100), funding raised ($35.8M against $12.0M).
Read the full 32 Biosciences review and pricing or the Mabylon review and pricing. You can also browse other 32 Biosciences alternatives we track.